According to the Legislative Budget Board (LBB), The fiscal implications of SB 1263 primarily involve new costs associated with administering the Prescription Drug Disposal Pilot Program (PDDPP), which will be overseen by the Department of State Health Services (DSHS) and funded through the Opioid Abatement Account (Account No. 5189). The bill itself does not make an appropriation but establishes a legal framework enabling the legislature to appropriate funds in future sessions.

Over the five-year period from fiscal year 2026 to 2030, the program is projected to cost approximately $746,000–$896,000 annually. These costs will cover one-time and recurring expenses related to drug collection receptacles at up to 100 pharmacies. Each participating pharmacy will receive a one-time installation fee, kiosk equipment, and regular supply kits, with estimated first-year costs of $4,050 per location and annual recurring costs of $1,950 thereafter. DSHS will also launch a public education campaign costing $250,000 per year to promote safe drug disposal practices statewide.

The program will require 2 full-time equivalent (FTE) employees—Program Specialist VI positions—who will ensure compliance with federal DEA requirements, manage vendor contracts, coordinate pharmacy enrollment, and oversee logistical operations. These personnel costs are estimated at $241,265 in FY 2026 and $301,180 in FY 2027 and subsequent years.

Importantly, no fiscal impact to General Revenue Funds is anticipated, and there are no expected fiscal implications for local governments. The Texas State Board of Pharmacy, which previously housed the pilot program but never received implementation funding, is unaffected by the administrative transfer. Similarly, the Health and Human Services Commission is expected to absorb any administrative rulemaking costs within existing resources.

While well-intentioned, SB 1263 represents a government-led approach to a problem that the private sector is already well-equipped to address. Pharmacies, healthcare providers, and even federal programs like the DEA’s National Take Back Initiative already offer safe, effective, and voluntary mechanisms for drug disposal, without creating new state infrastructure or recurring costs.

This bill establishes a pilot program, but as is often the case, the pilot is likely to become permanent. It commits nearly $900,000 in the first year and over $700,000 annually thereafter from the Opioid Abatement Fund, including the hiring of new state employees. Those are funds that could be more directly used for treatment, prevention, or local recovery initiatives with proven results. Once the infrastructure is in place, it will be politically and logistically difficult to scale back, regardless of performance.

Moreover, SB 1263 expands state health bureaucracy by transferring program authority to the Department of State Health Services. It adds administrative and regulatory complexity when a leaner, market-based approach would better align with Texas’s tradition of innovation, decentralization, and fiscal prudence.

For these reasons—government expansion, potential long-term costs, duplicative services, and the crowding out of private innovation—Texas Policy Research recommends that lawmakers vote NO on SB 1263.

• Individual Liberty: The bill empowers individuals by improving access to safe and convenient ways to dispose of unused or expired medications. For those concerned about drug misuse, accidental poisoning, or environmental harm, the added infrastructure may increase personal security and control over household pharmaceuticals. However, because the program is government-led and publicly funded, some may argue it risks displacing private alternatives that preserve choice without government intervention.
• Personal Responsibility: On one hand, the bill encourages responsible behavior by making it easier to dispose of drugs properly. On the other, it removes the incentive for individuals to seek out private or existing solutions by subsidizing the convenience through public funds. This creates a tension: the government is facilitating responsible behavior, but doing so in a way that may reduce the expectation that individuals take initiative or bear the cost themselves.
• Free Enterprise: The bill could disincentivize private-sector solutions by introducing a state-funded competitor. Pharmacies and waste management vendors already offer drug disposal services on a commercial basis. By funding kiosks through the state and paying pharmacies to participate, the bill may distort market dynamics and discourage innovation or expansion in the private sector.
• Private Property Rights: The bill respects property rights by making pharmacy participation voluntary. It does not mandate that businesses host receptacles or surrender autonomy. It also allows pharmacies to contract with DEA-registered vendors of their choosing. However, if the program were later expanded or mandates introduced, it could begin to encroach on business decision-making.
• Limited Government: This is where the bill draws the strongest concern. It creates a new ongoing function within the Department of State Health Services, adds permanent FTEs, and authorizes a new use of Opioid Abatement Funds—all to carry out a function that the private sector already provides in many communities. While labeled as a "pilot," it has the architecture of a permanent program, increasing the size, scope, and budgetary footprint of state government.

• HB 5248 (Same As)